ALX Oncology Holdings Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- ALX Oncology Holdings Inc. is a clinical-stage biotechnology company dedicated to developing novel immuno-oncology therapies to treat cancer by enhancing the immune system's ability to target and kill cancer cells. Its core products include evorpacept, a CD47-blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated proprietary Fc domain, designed to serve as a cornerstone therapy in immuno-oncology. This therapy is being evaluated in multiple ongoing clinical trials across a range of cancer indications and is combined with anti-cancer antibodies, antibody-drug conjugates (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. ALX Oncology’s second lead product candidate is ALX2004, a novel epidermal growth factor receptor (EGFR)-targeted ADC designed with an affinity-tuned antibody backbone, a proprietary topoisomerase I inhibitor payload with an enhanced bystander effect, and a stable linker. ALX2004 entered a Phase 1 clinical trial in August 2025 aimed at treating multiple EGFR-expressing solid tumors. Since its founding, the company has focused on leveraging advanced protein engineering technologies to overcome challenges associated with CD47 blockade and develop synergistic therapies with a primary emphasis on antibody-dependent cellular phagocytosis. In recent years, ALX Oncology made significant strategic moves, including its 2021 acquisition of ScalmiBio, which expanded its pipeline with proprietary cytotoxic payloads and SHIELD technology to enhance ADC development and therapeutic safety profiles. Key recent developments include the August 2025 clinical trial initiation for ALX2004 and promising preclinical data demonstrating potent anti-tumor activity and favorable safety profiles including no common toxicities seen in EGFR-targeted treatments. Additionally, the company is prioritizing evorpacept’s development in combination regimens for indications such as HER2-positive breast and gastric cancers, targeting patient populations with unmet therapeutic needs. ALX Oncology maintains partnerships with leading pharmaceutical companies and academic institutions to broaden the clinical development and therapeutic applications of its pipeline. The company operates primarily in the United States with a focus on advancing cancer treatments through immuno-oncology and antibody-drug conjugate platforms. ALX Oncology is headquartered in South San Francisco, California, and was established to address critical gaps in cancer therapy by developing biologic drugs that bridge innate and adaptive immune responses. Its pipeline and clinical strategy reflect a comprehensive approach to extending patient lives through innovative immuno-oncological mechanisms and combination therapies integrating its core molecules with other cancer treatments. The company continues to expand its clinical programs and collaborations, reinforcing its role as a clinical-stage biopharmaceutical innovator in the oncology sector.
ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?
ALX Oncology Holdings Inc. (ALXO) Q1 2026 Earnings Call Transcript
ALX Oncology Q1 Earnings Call Highlights
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update
ALX Oncology's Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression
ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest Update
ALX Oncology Q4 Earnings Call Highlights
ALX Oncology Holdings Inc. (ALXO) Q4 2025 Earnings Call Transcript
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026
ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026
Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?
Corey Goodman Acquires 3,184,713 Shares of ALX Oncology (NASDAQ:ALXO) Stock
Market Today: Tech Slump, Google AI Spend, Bitcoin Slide
ALX Oncology Announces Pricing of Underwritten Offering